The availability of specialized maternal mental health care varies significantly by geography, with North America and Europe currently leading the way in the adoption of PPD-specific drugs. In these regions, high awareness and advanced healthcare infrastructure have made it possible for many women to access the latest treatments. However, a deep dive into each Postpartum Depression Drug Market...

According to a new report from Intel Market Research, the global Esketamine market was valued at USD 1.05 billion in 2025 and is projected to reach USD 2.15 billion by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is driven by rising mental health awareness, increasing prevalence of treatment-resistant depression, and expanding therapeutic...

The Global Mirtazapine Tablets Market is expected to reach US$1,401.34 million by 2034, up from US$916.49 million in 2025, registering a CAGR of 4.83% during the forecast period 2026–2034. Market growth is being supported by continued demand for antidepressant therapies, increasing awareness of mental health conditions, the need for effective pharmacological...

The global neuromodulation devices market was valued at USD 6.4 billion in 2025 and is projected to grow from USD 7.0 billion in 2026 to USD 13.9 billion by 2033, expanding at a CAGR of 10.4%. North America leads with a 43.4% revenue share, spinal cord stimulators are the top-selling product, and Parkinson's disease is the largest application segment. Neuromodulation — the use...

"Comprehensive Outlook on Executive Summary Pharmacogenetics Testing in Psychiatry/Depression Market Size and Share CAGR Value The global pharmacogenetics testing in psychiatry/depression market size was valued at USD 1.34 billion in 2024 and is expected to reach USD 2.97 billion by 2032, at a CAGR of 10.4% during the forecast period The insights...

Vagus nerve stimulation devices deliver electrical impulses to the vagus nerve to support the management of certain neurological disorders. Growing healthcare investments, increasing awareness of neuromodulation therapies, and the gradual expansion of specialized medical infrastructure are supporting market growth across Africa. According to Business Market Insights, the Africa Vagus...

Productivity and Mental Health Mental health is no longer just a medical issue; it's a massive economic one. Depression is the leading cause of disability worldwide. The cost to the global economy is estimated in the trillions, primarily due to "Presenteeism"—when employees are at work but not fully functional. This economic reality is forcing insurance companies and governments to...

The financial commitment to mental health infrastructure has seen a dramatic increase as governments recognize the high cost of untreated depression on national productivity. Absenteeism and "presenteeism"—where employees are physically at work but mentally checked out—cost the global economy trillions of dollars annually. Consequently, public and private sectors are funneling...